The Company has announced the Outcome of the Board meeting held on May 19, 2026, including approval of audited financial results of the Company for the quarter and year ended March 31, 2026.
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.3 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
HCG reported FY2026 standalone revenue of Rs 1,359 crore, up 6.5% from Rs 1,277 crore in FY2025. Net profit declined to Rs 14.6 crore from Rs 16.1 crore, impacted by exceptional items totaling Rs 5,538 lakh loss, primarily from BACC divestment impairment (Rs 3,752 lakh) and Kolkata subsidiary impairment (Rs 3,000 lakh), partially offset by Manavata reversal (Rs 2,000 lakh). The company completed a Rs 425 crore rights issue in March 2026. The Board approved divestment of BACC Healthcare (fertility business, non-core) to Inviga Healthcare Fund I for Rs 37.64 crore, classified as a related party transaction. Auditors B S R & Co. LLP issued unmodified (clean) opinion on both standalone and consolidated results.
Clean audit opinion provides earnings quality confidence, but profit decline from impairments may create near-term negative sentiment. BACC divestment reduces non-core exposure and strengthens balance sheet, while the Rs 425 crore capital raise provides growth firepower.